Small Molecules that Enhance the Pharmacological Effects of Oligonucleotides Melissa Porter 1, Bing Yang 1, Canhong Cao 1, Xin Ming 1, Emily Hull-Ryde.

Slides:



Advertisements
Similar presentations
The Drug Discovery Process
Advertisements

rhBMP-2: origin, biology and preclinical safety
Novel Modulators of Ah Receptor Signaling
Discussion Our current results suggest that it is possible to identify susceptibility regions using this methodology. The presented method takes advantage.
Inhibition of SHH signaling enhances Docetaxel efficacy in castration-resistant prostate cancer cells Sierra L. Lawhorne 1,2, Sakthivel Muniyan 1, Parthasarathy.
Bioinformatics Ayesha M. Khan Spring Phylogenetic software PHYLIP l 2.
Drug discovery and development
U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke U.S. DEPARTMENT OF HEALTH.
Cells Treated with serial diluted compound and incubated for 24 hours Evaluating the Effects of Small Molecule Drugs on Correcting Alternative Splicing.
Marine Drug Development and Delivery Prof. Dr. Basavaraj K. Nanjwade M. Pharm., Ph. D Department of Pharmaceutics KLE University College of Pharmacy BELGAUM ,
Biomedical Research.
Isosteviol derivatives induced apoptosis in Human lung cancer via targeting MEK/MAPK pathway: An in vitro and in vivo study Ahmed M Malki 1,,PhD Stephen.
Infectivity Enhanced Adenovirus as a Strategy for Improving the Efficiency of RNA Interference in an Ovarian Cancer Model T Michael Numnum, MD International.
Transfection.
Nanotechnology in Cancer Treatment
Acknowledgement of funding Regulator of G-protein signaling 5 blunts cellular viability mediated by a stabilized lysophosphatidic acid analogue (2S-OMPT)
Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.
Gene Therapy (IV) “Strategies and Applications” Dr. Aws Alshamsan Department of Pharmaceutics Office: AA87 Tel:
Km23: a Novel Protein in the TGF  Signaling Pathway Nicole Dague Department of Biological Sciences, York College of Pennsylvania ABSTRACT An innovative.
The Use of a Vesicular Delivery System in the Enhancement of Cisplatin Bioavailability Manal M. Alsaadi, Katharine C. Carter and Alexander B. Mullen Strathclyde.
Therapeutic miRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model Janaiah Kota,1 Raghu R. Chivukula,2 Kathryn A. O’Donnell,3,4 Erik A.
ECCR Overview/MLSCN. NIH Roadmap Series of initiatives designed to pursue major opportunities in biomedical research and gaps in current knowledge that.
© Paradigm Publishing, Inc.1 Chapter 2 Basic Concepts of Pharmacology.
Gene therapy Lecture 8. What is a liposome? ◦ Spherical vesicles with a phospholipid bilayer Hydrophilic Hydrophobic.
Cancer Therapies DNA microarrays are used to assess the relative expression of thousands of genes simultaneously—relative expression means that.
Products > SKNAS Transfection Reagent (Neuroblastoma Cells) Altogen Biosystems offers the SKNAS Transfection Reagent among a host of 100+ cell line specific.
Altogen Biosystems  848 Rainbow Blvd #823  Las Vegas  NV   USA Telephone   Fax   
Basic Concepts of Pharmacology © Paradigm Publishing, Inc.
UPDATE ON SCA RESEARCH George Wilmot, MD, PhD. DISCLAIMER  The information provided by speakers in any presentation made as part of the 2016 NAF Annual.
Products > PC-3 Transfection Reagent (Prostate Cancer Cells) Altogen Biosystems offers the PC-3 Transfection Reagent among a host of 100+ cell line specific.
Products > Astrocyte Transfection Reagent (Primary Astrocyte Cells, Astroglia) Altogen Biosystems offers the Astrocyte Cell Transfection Reagent among.
Transfection can be accomplished through the use of cationic polymers such as DEAE-dextran or polyethylenimine. The negatively charged DNA binds to the.
Products > MCF-7 Transfection Reagent (Breast Cancer, HTB-22) Altogen Biosystems offers the MCF-7 Transfection Reagent among a host of 100+ cell line specific.
A substance used in the diagnosis, treatment, or prevention of a disease or as a component of a medication recognized or defined by the U.S. Food, Drug,
Lipofection (or liposome transfection) is a technique used to inject genetic material into a cell by means of liposomes, which are vesicles that can easily.
Products > AGS Transfection Reagent (Gastric Adenocarcinoma, CRL1739) Altogen Biosystems offers the AGS Transfection Reagent among a host of 100+ cell.
Products > Liver In Vivo Transfection Kit
Products > Pancreas In Vivo Transfection Kit
Drug Discovery &Development
RNAi Overview
Products > CFPEo (HTRpC) Transfection Reagent (Trachea Epithelium)
Products > 4T1 Transfection Reagent (Breast Cancer Cells, CRL-2539)
Products > CHO Transfection Reagent (Chinese Hamster Ovary Cells)
Ke Xu, Ph.D. Putuo Hospital and Cancer Institute,
Products > BT-20 Transfection Reagent (Breast Carcinoma Cells)
Products > CT26.WT Transfection Reagent (Colon Carcinoma)
APPLICATIONS OF BIOINFORMATICS IN DRUG DISCOVERY
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
An Introduction to Medicinal Chemistry 3/e
Products > Keratinocyte Transfection Reagent (Keratinocytes)
From Bench to Clinical Applications: Money Talks
Michael C. Pribula, Andras K. Ponti, and Erin E. Johnson
Bystander Effects.
Early Cognitive Decline and the Aging Brain - Overview
Products > KB Transfection Reagent (Mouth Epidermal Carcinoma)
Altogen labs Leading Developer and Manufacturer of In Vivo and DNA Transfection Kits, Transfection Reagents and Electroporation Delivery Products Products.
Kathleen M. Schoch, Timothy M. Miller  Neuron 
Molecular Therapy - Nucleic Acids
Autophagy in the Pathogenesis of Disease
Personalized Medicine: Patient-Predictive Panel Power
Rational for the 5R Philosophy
Volume 19, Issue 9, Pages (September 2011)
miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK
Products > LS-174T Transfection Reagent (Colon Adenocarcinoma)
Products > CLBPEC Transfection Reagent (Neuroblastoma Cells)
Possible Joint Development Project between the Town of Chapel Hill and the University of North Carolina at Chapel Hill March 6, 2017.
IMPORTANT USAGE PARAMETERS
IMPORTANT USAGE PARAMETERS
Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.
Presentation transcript:

Small Molecules that Enhance the Pharmacological Effects of Oligonucleotides Melissa Porter 1, Bing Yang 1, Canhong Cao 1, Xin Ming 1, Emily Hull-Ryde 1, Joseph Maddry 2, Mark Suto 2, William Janzen 3 and Rudolph Juliano 1 1 Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC Southern Research Institute, Birmingham, AL Epizyme, Inc, 400 Technology Square, Cambridge, MA Center for Integrative Chemical Biology and Drug Discovery Funding: This work was supported by Federal Funds from the National Institute of Health, under grants #R01CA and R21CA to RLJ, and by an award from the University Cancer Research Fund of UNC. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. Figures taken from: High Throughput Screening Identifies Small Molecules that Enhance the Pharmacological Effects of Oligonucleotides. Yang, Bing ; Ming, Xin; Cao, Canhong; Laing, Brian; Yuan, Ahu; Porter, Melissa; Hull-Ryde, Emily; Maddry, Joseph; Suto, Mark; Janzen, William; Juliano, Rudolph (in press Nucleic Acids Research) Acknowledgements Overview For almost two decades there has been strong interest in the potential use of antisense and siRNA oligonucleotides for cancer therapy. Despite much research, as well as FDA approval of the first antisense drug and the advent of multiple clinical trials in cancer and other diseases, the development of oligonucleotides as therapeutic agents has progressed only slowly. A major issue has been the poor delivery of these large, highly polar molecules to their sites of action in the cytosol or nucleus of target tissues and cells. We believe that this problem can be addressed using small molecules to enhance the effects of oligonucleotides by modulating their intracellular trafficking and release from endosomes. To this end, we designed and executed a high throughput screen of >150,000 compounds and identified three classes of oligonucleotide enhancing small molecules. These agents act on several forms of nucleic acids including antisense, splice switching and siRNA oligonucleotides, are active in the low micromolar range and can increase effectiveness of oligonucleotides to an extent comparable to cationic lipid transfection agents. Preliminary in vivo studies suggest that they are active when administered at non-toxic doses. Abstract Screen Results Dose Response and Cytotoxicity Conclusions Hi gh Throughput Screen Assay Primary author contact: Goal: Use oligonucleotides (splice switching, antisense, SiRNA) as therapeutics Problem: Oligonucleotides are taken up by cells via endocytosis and get stuck in endosomes, limiting their activity Solution: Use small molecules to enhance delivery of oligonucleotides to their site of action by modulating their intracellular trafficking. Effect on ASO and SiRNA Oligo Subcellular Localization In Vivo Entrapment of oligonucleotides in endosomes is a major constraint on their pharmacological action Our studies demonstrate that HTS can identify small molecule enhancers of oligo activity and make the case for additional screening for more potent molecules with less toxicity. It is possible to release oligos from endosomes using a small molecule The intracellular trafficking, rather than the direct action of the oligo, is influenced by the small molecule Small molecules were screened based on their ability to greatly enhance luciferase induction via SSO623. We identified 3 compounds of interest. Hits were confirmed with dose response curves using the primary assay. False positives that increased spontaneous splice correction were identified and discarded. Confirmed hits were tested in the luciferase induction assay in a 24 well format and results normalized to cell protein concentration. Luciferase expression was enriched when the compounds were used in the  M range. To address whether the compounds directly affected the splicing process or the delivery of the oligos to the nucleus and cytosol, we looked at several types of oligos (SSO, ASO, siRNA), each having different mechanisms of action UNC7938 enhanced the ability of an siEGFP to reduce the levels of EGFP in a cell line stably expressing the reporter. Oligo accumulation was seen in the nucleus with compound treatment When EGFP654 transgenic mice were administered SSO with UNC7938, an increase in EGFP was observed in tissues HelaLuc705 cells contain a luciferase reporter interrupted by an abnormal intron. Reporter expression can be restored by a Splice Switching Oligo (SSO623). Cytotoxicity was assessed using Alamar Blue. Cells were exposed to compounds for 5 hours and then recovered an additional 24 hours. Only minimal toxicity was observed at a compound concentration of 10  M. UNC7938 enhanced the antisense knockdown of MDR1 in multi-drug resistant NIH-3T3 cells. The effect of UNC7938 was compared to a commercial cationic lipid, Lipofectamine 2000 (L2K). Treatment with UNC7938 led to a decrease of oligo in late endosomes (Rab7); presence in the lysosomes (LAMP1) was not affected